Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (09) : 952-955     DOI: 10.3971/j.issn.1000-8578.2022.22.0034
|
Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases
HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450003, China
Download: PDF(7433 KB)   ( 20 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the clinical efficacy and prognostic factors of autologous hematopoietic stem cell transplantation (ASCT) for Hodgkin’s lymphoma (HL). Methods We retrospectively analyzed the data of 38 patients with HL who underwent ASCT. Kaplan-Meier and Cox methods were used to analyze the curative effect and prognostic factors after transplantation. Results All 38 transplanted patients obtained hematopoietic reconstitution. The CR rates before and after transplantation were 55.3% and 81.6%, respectively, and the 5-year PFS and OS were 76.1% and 79.0%, respectively. Univariate analysis showed that B symptoms, IPS score, pre-transplant remission status, extranodal invasion, and pretreatment regimen were the factors affecting the prognosis of ASCT in patients with HL. Multivariate analysis showed that B symptom was an independent risk factor affecting 5-year PFS. Conclusion ASCT is effective in the treatment of high-risk, relapsed, and refractory patients with HL. B symptom is an independent risk factor affecting the prognosis of transplantation.
Keywords Hematopoietic stem cell transplantation      Autologous      Hodgkin’s lymphoma      Prognosis      Curative effect     
ZTFLH:  R733.4  
Issue Date: 15 September 2022
 Cite this article:   
HUANG Zhenghua,ZHOU Jian,LI Yufu, et al. Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 952-955.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0034
http://www.zlfzyj.com/EN/Y2022/V49/I09/952
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
HUANG Zhenghua
ZHOU Jian
LI Yufu
LIU Yanyan
ZHOU Keshu
SONG Yongping
[1] Momotow J, Borchmann S, Eichenauer DA, et al. Hodgkin<br /> lymphoma-re view on pathogenesis, diagnosis, current and future<br /> treatment approaches for adult patients[J]. J Clin Med, 2021,<br /> 10(5): 1125.<br /> [2] Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis, riskstratification,<br /> and management[J]. Am J Hematol, 2020, 95(8):<br /> 978-989.<br /> [3] Roerden M, S?kler M, Kanz L, et al. Outcome after autologous<br /> stem cell transplantation in primary refractory or relapsed Hodgkin<br /> lymphoma-a long-term follow-up single center experience[J]. Ann<br /> Hematol, 2020, 99(2): 265-276.<br /> [4] Xie Y, Wang X, Leng X, et al. High-dose chemotherapy followed<br /> by autologous stem cell transplantation for patients with<br /> refractory/relapsed classical Hodgkin lymphoma: A single center<br /> experience from China[J]. Ann Hematol, 2020, 99(3): 549-555.<br /> [5] Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcome of children<br /> and adolescents with relapsed Hodgkin lymphoma treated with<br /> high-dose therapy and autologous stem cell transplantation: The<br /> Memorial Sloan Kettering Cancer Center experience[J]. Leuk<br /> Lymphoma, 2018, 59(8): 1861-1870.<br /> [6] Zou DM, Zhou DB, Zhang Y, et al. Clinical characteristics and<br /> prognostic factors in Chinese patients with classical Hodgkin's<br /> lymphoma involving extranodal sites: A retrospective singlecenter[<br /> J]. Hematology, 2019, 24(1): 661-668.<br /> [7] Singer S, Dean R, Zhao Q, et al. BEAM versus BUCYVP16<br /> conditioning before autologous hematopoietic stem cell transplant<br /> in patients with Hodgkin lymphoma[J]. Biol Blood Marrow<br /> Transplant, 2019, 25(6):1107-1115.<br /> [8] 喻凤宽, 周健, 李玉富, 等. BEAC预处理自体造血干细胞移<br /> 植治疗淋巴瘤的疗效观察[J]. 肿瘤防治研究, 2011, 38(11):<br /> 1324-1325, 1340. [Yu FK, Zhou J, Li YF, et al. Observation of<br /> the effect of BEAC preconditioning on autologous hematopoietic<br /> stem cell transplantation in lymphoma[J]. Zhong Liu Fang Zhi<br /> Yan Jiu, 2011, 38(11): 1324-1325, 1340.]<br /> [9] Halacoglu A, Serefhanoglu S. A retrospective comparison of<br /> mitoxantrone-melphalan and BEAM conditioning regimens<br /> before autologous hematopoietic stem cell transplantation in<br /> relapsed/refractory lymphoma patients[J]. Indian J Hematol Blood<br /> Transfus, 2022, 38(1): 92-98.<br /> [10] Hasenclever D, Diehl V. A prognostic score for advanced<br /> Hodgkin's disease. international prognostic factors project on<br /> advanced Hodgkin's disease[J]. N Engl J Med, 1998, 339(21):<br /> 1506-1514.<br /> [11] Diefenbach CS, Li H, Hong F, et al. Evaluation of the International<br /> Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3)<br /> for advanced Hodgkin lymphoma in the modern era[J]. Br J<br /> Haematol, 2015, 171(4): 530-538.<br /> [12] O'Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus<br /> bendamustine in relapsed or refractory Hodgkin’s lymphoma: An<br /> international, multicentre, single-arm, phase 1-2 trial[J]. Lancet<br /> Oncol, 2018, 19(2): 257-266.<br /> [13] Crump M. Time to change direction in the treatment of relapsed<br /> Hodgkin lymphoma? [J]. J Clin Oncol, 2021, 39(2): 97-99.<br /> [14] Andrade-Gonzalez X, Ansell SM. Novel therapies in the treatment<br /> of Hodgkin lymphoma[J]. Curr Treat Options Oncol, 2021, 22(5):<br /> 42.
Related articles from Frontiers Journals
[1] LIU Yao, SUN Xuemei, LIU Jing, LIU Wei, LYU Fei, LIU Yueping. Expression of FGL1, Distribution of Tumor-Infiltrating Lymphocytes, and Their Clinical Significance in Esophageal Squamous-Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1043-1047.
[2] WANG Zhihui, ZHANG Shuijun. Influence of Multidisciplinary Combined Therapy on Curative Effect of Liver Cancer Treatment[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 880-885.
[3] LI Jinzhou, WANG Wenjie, YAO Yalong, MU Yanxi, CHEN Kang, SHEN Yimin, WANG Zhou, HUANG Zeping, CHEN Xiao. Development and Validation of Prognostic Nomogram Based on Negative Lymph Node Count for Patients with Gastric Signet Ring Cell Carcinoma#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 923-930.
[4] XU XiaoFei, LI Yang, CHEN Lingyun, DAI Heyang, XUE Jiaojiao, LI Qingxia, . Research Progress of PNI and CONUT in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 961-964.
[5] JIA Lijuan, ZHANG Yunqiang, ZHANG Baihong, YUE Hongyun. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
[6] SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
[7] LI Jinzhou, HUANG Zeping, MU Yanxi, YAO Yalong, WANG Wenjie, LIU Haipeng, LIU Jie, WANG Zhou, CHEN Xiao. Prognostic Value of Negative Lymph Nodes Count in Solid Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 843-849.
[8] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[9] XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 675-681.
[10] ZHAN Jianghua, WANG Zhiru, . Progress and Comment on Surgical Treatment of Hepatoblastoma in Children[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 541-545.
[11] . Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 586-592.
[12] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[13] LI Menghan, XIAO Qiong, GAO Peng, FU Yu, SUN Chenrui, SONG Yongxi. LncRNA Prognostic Risk Scoring Model for Gastrointestinal Tumors Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 606-611.
[14] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
[15] LEI Haike, LI Xiaosheng, LI Jieping, LIU Jun, XIAO Chunyan, WANG Ying, ZHANG Wei, LIU Yao, WU Yongzhong. Clinical Characteristics and Prognostic Influence Factors of Patients with AIDS-related Malignant Tumor[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 412-417.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed